JP2016531853A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531853A5
JP2016531853A5 JP2016516601A JP2016516601A JP2016531853A5 JP 2016531853 A5 JP2016531853 A5 JP 2016531853A5 JP 2016516601 A JP2016516601 A JP 2016516601A JP 2016516601 A JP2016516601 A JP 2016516601A JP 2016531853 A5 JP2016531853 A5 JP 2016531853A5
Authority
JP
Japan
Prior art keywords
composition
antigen
opls
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016516601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531853A (ja
JP6783652B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/057234 external-priority patent/WO2015048145A1/en
Publication of JP2016531853A publication Critical patent/JP2016531853A/ja
Publication of JP2016531853A5 publication Critical patent/JP2016531853A5/ja
Application granted granted Critical
Publication of JP6783652B2 publication Critical patent/JP6783652B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016516601A 2013-09-24 2014-09-24 抗原特異的免疫原性を低減するための組成物及び方法 Active JP6783652B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881857P 2013-09-24 2013-09-24
US61/881,857 2013-09-24
PCT/US2014/057234 WO2015048145A1 (en) 2013-09-24 2014-09-24 Compositions and methods for reducing antigen-specific immunogenicity

Publications (3)

Publication Number Publication Date
JP2016531853A JP2016531853A (ja) 2016-10-13
JP2016531853A5 true JP2016531853A5 (enExample) 2017-09-28
JP6783652B2 JP6783652B2 (ja) 2020-11-11

Family

ID=52744422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016516601A Active JP6783652B2 (ja) 2013-09-24 2014-09-24 抗原特異的免疫原性を低減するための組成物及び方法

Country Status (6)

Country Link
US (1) US20160243220A1 (enExample)
EP (1) EP3049103B1 (enExample)
JP (1) JP6783652B2 (enExample)
CN (1) CN105992591A (enExample)
ES (1) ES2807550T3 (enExample)
WO (1) WO2015048145A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192899A1 (en) * 2021-03-11 2022-09-15 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance
JP2024532810A (ja) * 2021-08-13 2024-09-10 ラピックス セラピューティクス， インコーポレイテッド 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
KR20240046882A (ko) 2021-08-13 2024-04-11 라픽스 테라퓨틱스, 인코포레이티드 면역 불내성의 감소 및 자가면역 장애의 치료를 위한 조성물 및 방법
CN121693562A (zh) 2022-10-25 2026-03-17 Lapix生物治疗股份有限公司 免疫细胞移植的非人动物和非人动物模型
WO2024118602A1 (en) 2022-11-29 2024-06-06 Lapix Therapeutics, Inc. Compositions and methods for reducing immune intolerance and treating autoimmune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7625584B2 (en) 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US7351688B2 (en) 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
US7875288B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
JP5160534B2 (ja) * 2006-03-30 2013-03-13 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物
EP2451485B1 (en) * 2009-07-07 2016-03-02 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance

Similar Documents

Publication Publication Date Title
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
JP2016513640A5 (enExample)
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
JP2016040284A5 (enExample)
JP2016506935A5 (enExample)
NZ630790A (en) Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP2018505882A5 (enExample)
JP2012193216A5 (enExample)
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
JP2015530399A5 (enExample)
MY189494A (en) Methods of administering beta7 integrin antagonists
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
RU2015134422A (ru) Применение левоцитиризина и монтелукаста при лечении васкулита
JP2016532516A5 (enExample)
JP2016534996A5 (enExample)
EP2925352A4 (en) HONESTICAL INVASIN FOR IMMUNIZATION, DIAGNOSIS AND CELL RELEASE
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
EP3054013A4 (en) IMMUNOGENOUS FORMULATION WITH RECOMBINANT LIVE BCG FOR THE EXPRESSION OF ANTIGENES OF METAPNEUMOVIRUS (HMPV) IN A SUSPENSION MADE FROM A LYOPHILISATE WITHOUT THE NEED FOR A PHARMACEUTICAL USE AGENT
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
JP2017502058A5 (enExample)
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
JP2010510218A5 (enExample)
RU2011108787A (ru) Способ лечения больных красным плоским лишаем слизистой полости рта